TrialClinical cancer research : an official journal of the American Association for Cancer Research2023

A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.